Search Results for: Diabetes

3097 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
ERBB3 and ITK erb-b2 receptor tyrosine kinase 3 IL2-inducible T-cell kinase
  • TCR signaling
  • Generation of second messenger molecules
  • Fc epsilon receptor (FCERI) signaling
  • FCERI mediated Ca+2 mobilization
  • Innate Immune System
  • Adaptive Immune System
  • Staurosporine
  • Pazopanib
ERBB3 and TNS3 erb-b2 receptor tyrosine kinase 3 tensin 3
ERBB3 and CD82 erb-b2 receptor tyrosine kinase 3 CD82 molecule
ERBB3 and TXK erb-b2 receptor tyrosine kinase 3 TXK tyrosine kinase
  • Fc epsilon receptor (FCERI) signaling
  • FCERI mediated Ca+2 mobilization
  • Innate Immune System
ERBB4 and SYK erb-b2 receptor tyrosine kinase 4 spleen tyrosine kinase
  • Signaling by the B Cell Receptor (BCR)
  • FCERI mediated MAPK activation
  • Platelet Aggregation (Plug Formation)
  • DAP12 signaling
  • Regulation of signaling by CBL
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • DAP12 interactions
  • Integrin alphaIIb beta3 signaling
  • Cytokine Signaling in Immune system
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Signaling by Interleukins
  • Fc epsilon receptor (FCERI) signaling
  • GPVI-mediated activation cascade
  • Interleukin-2 signaling
  • FCERI mediated Ca+2 mobilization
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic Acid
ERBB4 and NRG3 erb-b2 receptor tyrosine kinase 4 neuregulin 3
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • GRB2 events in ERBB2 signaling
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Nuclear signaling by ERBB4
  • SHC1 events in ERBB4 signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
ESR1 and HNF4A estrogen receptor 1 hepatocyte nuclear factor 4, alpha
  • Nuclear signaling by ERBB4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by ERBB4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated Estrogens
  • Etonogestrel
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone
  • Estrone
  • Tamoxifen
  • Estradiol
  • Ethynodiol Diacetate
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinyl Estradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Allylestrenol
  • Genistein
  • Compound 19
  • Compound 18
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estropipate
  • Quinestrol
  • Ospemifene
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • RALOXIFENE CORE
ESR1 and PPARG estrogen receptor 1 peroxisome proliferator-activated receptor gamma
  • Nuclear signaling by ERBB4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by ERBB4
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated Estrogens
  • Etonogestrel
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone
  • Estrone
  • Tamoxifen
  • Estradiol
  • Ethynodiol Diacetate
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinyl Estradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Allylestrenol
  • Genistein
  • Compound 19
  • Compound 18
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estropipate
  • Quinestrol
  • Ospemifene
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • RALOXIFENE CORE
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
ESR2 and PPARG estrogen receptor 2 (ER beta) peroxisome proliferator-activated receptor gamma
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Diethylstilbestrol
  • Raloxifene
  • Tamoxifen
  • Estradiol
  • Trilostane
  • Estramustine
  • Genistein
  • Para-Mercury-Benzenesulfonic Acid
  • N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide
  • 5-Alpha-Androstane-3-Beta,17beta-Diol
  • 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol
  • Estriol
  • Estropipate
  • 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL
  • 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
  • (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL
  • (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
FABP1 and PPARG fatty acid binding protein 1, liver peroxisome proliferator-activated receptor gamma
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
FBLN1 and TCF7L2 fibulin 1 transcription factor 7-like 2 (T-cell specific, HMG-box)
  • Molecules associated with elastic fibres
  • Elastic fibre formation
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
FKBP4 and PTPN2 FK506 binding protein 4, 59kDa protein tyrosine phosphatase, non-receptor type 2
  • HSF1-dependent transactivation
  • Attenuation phase
  • Cellular response to heat stress
FOXO1 and PPARG forkhead box O1 peroxisome proliferator-activated receptor gamma
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Regulation of beta-cell development
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • AKT-mediated inactivation of FOXO1A
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Regulation of gene expression in beta cells
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
FOXO1 and HNF4A forkhead box O1 hepatocyte nuclear factor 4, alpha
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Regulation of beta-cell development
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • AKT-mediated inactivation of FOXO1A
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Regulation of gene expression in beta cells
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
FLNA and SH2B3 filamin A, alpha SH2B adaptor protein 3
  • Cell junction organization
  • GP1b-IX-V activation signalling
  • Response to elevated platelet cytosolic Ca2+
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Cell-extracellular matrix interactions
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Factors involved in megakaryocyte development and platelet production
FLNA and MTNR1B filamin A, alpha melatonin receptor 1B
  • Cell junction organization
  • GP1b-IX-V activation signalling
  • Response to elevated platelet cytosolic Ca2+
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Cell-extracellular matrix interactions
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Ramelteon
  • Melatonin
  • Agomelatine
FOS and HNF1A FBJ murine osteosarcoma viral oncogene homolog HNF1 homeobox A
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • Senescence-Associated Secretory Phenotype (SASP)
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Oxidative Stress Induced Senescence
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
  • Nadroparin
FOSL2 and CREB5 FOS-like antigen 2 cAMP responsive element binding protein 5
FYN and CD226 FYN proto-oncogene, Src family tyrosine kinase CD226 molecule
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Host Interactions of HIV factors
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by VEGF
  • Downstream signal transduction
  • Sema3A PAK dependent Axon repulsion
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Platelet Adhesion to exposed collagen
  • Axon guidance
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • CTLA4 inhibitory signaling
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • PECAM1 interactions
  • CD28 dependent Vav1 pathway
  • Signaling by FGFR
  • Cell surface interactions at the vascular wall
  • GPVI-mediated activation cascade
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Adaptive Immune System
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
FYN and PRKCQ FYN proto-oncogene, Src family tyrosine kinase protein kinase C, theta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Host Interactions of HIV factors
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by VEGF
  • Downstream signal transduction
  • Sema3A PAK dependent Axon repulsion
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Platelet Adhesion to exposed collagen
  • Axon guidance
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • CTLA4 inhibitory signaling
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • PECAM1 interactions
  • CD28 dependent Vav1 pathway
  • Signaling by FGFR
  • Cell surface interactions at the vascular wall
  • GPVI-mediated activation cascade
  • G alpha (q) signalling events
  • Signaling by GPCR
  • Downstream TCR signaling
  • Axon guidance
  • Effects of PIP2 hydrolysis
  • FCERI mediated NF-kB activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • The phototransduction cascade
  • Programmed Cell Death
  • G alpha (z) signalling events
  • Netrin-1 signaling
  • Innate Immune System
  • Apoptotic cleavage of cellular proteins
  • Apoptotic execution phase
  • Diseases associated with visual transduction
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • TCR signaling
  • Visual phototransduction
  • Fc epsilon receptor (FCERI) signaling
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
  • Staurosporine
  • Phosphonothreonine
  • Phosphonoserine

Page 15 out of 155 pages